ICCC (ImmuCell) Total Debt per Share: $1.37 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
51 GF Score
Price $9.85
GF Value $6.91
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Total Debt per Share?

ImmuCell ICCC -2.81% 51 Total Debt per Share is $1.37 as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 51/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review.

$1.37 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. ImmuCell's Total Debt Per Share for the quarter that ended in Jun. 2026 was $1.37.

ImmuCell Total Debt per Share Historical Data

* Premium members only.

The historical data trend for ImmuCell's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Total Debt per Share Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 1.61 2.15 1.68 1.46

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.50 1.46 1.41 1.37
ICCC
51GF Score
ImmuCell Corp ICCC
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell Total Debt per Share Calculation

ImmuCell's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(11.50+1.70)/9.05
=1.46

ImmuCell's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(10.82+1.63)/9.08
=1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $1.37 mean?
ImmuCell (ICCC) has a Total Debt per Share of $1.37 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on ImmuCell and its competitors.
Is ImmuCell's Total Debt per Share too high?
ImmuCell's current Total Debt per Share is $1.37. Overall, ImmuCell has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Total Debt per Share compare to COYA and ENTX?
ImmuCell's Total Debt per Share of $1.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on ImmuCell and its competitors. ImmuCell's current Total Debt per Share is $1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $9.85 — trading 42.5% above its estimated fair value. The current Total Debt per Share is $1.37. ImmuCell's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For ImmuCell (ICCC), the current Total Debt per Share is $1.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $9.85 is trading 42.5% above its estimated GF Value™ of $6.91. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • Total Debt per Share: $1.37
  • GF Value™: $6.91 vs. price of $9.85 (42.5% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
51GF Score

Get the complete analysis for ICCC

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.85
Price
$6.91
GF Value